-- Preparing for the Initiation of Phase III Development with Complement 5a Receptor Inhibitor Avacopan (CCX168) for the Treatment of ANCA Vasculitis -- -- Reported Positive Data from Ongoing Pilot Phase II Trial of Avacopan in Patients with Atypical Hemolytic Uremic Syndrome -- -- Highlighted
-- Oral presentation at the American Society of Nephrology (ASN) Kidney Week 2016 to highlight Phase II AAV CLEAR trial results -- -- Oral presentation at the American College of Rheumatology (ACR) 2016 Annual Meeting to highlight Phase II AAV CLASSIC trial results -- MOUNTAIN VIEW, Calif. , Nov.
MOUNTAIN VIEW, Calif. , Oct. 28, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's third quarter 2016 financial results will be released after market close on Monday, November 7, 2016 . ChemoCentryx executive management will host a conference call
MOUNTAIN VIEW, Calif. , Oct. 20, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that effective October 17, 2016 , Henry A. McKinnell , Jr, Ph.D., retired chairman and chief executive officer of Pfizer Inc., has been appointed to the Company's Board of Directors.
-- CCX872 reduced hepatic inflammation, steatosis, and scarring in models of non-alcoholic steatohepatitis (NASH) -- -- Findings reported at the American College of Gastroenterology (ACG) 2016 Annual Meeting -- MOUNTAIN VIEW, Calif. , Oct. 18, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif. , Aug. 25, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J.
-- Successfully Completed Phase II ANCA-Associated Vasculitis (AAV) Development Program of Complement 5a Receptor Inhibitor CCX168 -- -- Awarded EMA PRIority MEdicines (PRIME) Designation for Accelerated Assessment of CCX168 in AAV, as well as FDA Orphan Products Development Grant for CCX168 for